ArticleERJ open research2025
Endobronchial valve treatment improves diaphragm function in severe emphysema patients.
Article in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Endobronchial Valve Treatment Improves Regional Specific Ventilation in the Target Lung.Respiration; international review of thoracic diseases · 2026Article
- Advancing towards personalized medicine: Practical specifications for management of treatable traits in patients with COPD exacerbations.Therapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diaphragm dysfunction is common in severe emphysema patients, primarily due to hyperinflation, placing the diaphragm at a mechanical disadvantage. Endobronchial valve (EBV) treatment is a bronchoscopic procedure to reduce hyperinflation and thus potentially restore diaphragm function in this patient population. Our aim was to investigate the effect of EBV treatment on diaphragm function. Methods: A prospective cohort study was performed in which diaphragm function was measured at baseline and 6 weeks after EBV treatment by ultrasonic assessment to measure diaphragm motion and diaphragm thickening fraction, surface electromyography (sEMG) to quantify diaphragm activity, and maximal inspiratory pressure to assess diaphragm strength. Results: 25 patients were included, with a mean±sd age of 64±7 years. Mean±sd residual volume (-0.85±0.49 L; p<0.001) decreased significantly post-EBV treatment, with a significant increase in median (range) maximal inspiratory pressure (0.6 (-1.2-2.8) kPa; p=0.001). Median (range) diaphragm motion on the treated side during tidal breathing significantly decreased (-3.3 (-24.7-14.6) mm; p=0.023). There were no significant changes in diaphragm thickening fraction on the treated side. Median (range) diaphragm activity (sEMG) for tidal breathing (-1.7 (-8.8-5.8) µV; p=0.004), maximal inspiration (-4.1 (-42.3-16.0) µV; p=0.004) and sniff manoeuvre (-6.1 (-42.2-24.2) µV; p=0.027) all significantly decreased. Conclusions: Our results show that diaphragm function significantly improves after EBV treatment in severe emphysema patients. This emphasises the physiological interaction between hyperinflation and diaphragm function, suggesting that reducing hyperinflation can at least partially reverse diaphragm dysfunction.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.